New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 14, 2014
12:47 EDTAGN, VRXAllergan slides question Valeant growth, disclosures, says BMO Capital
BMO Capital says Allergan (AGN) issued new slides today calling into question Valeant's (VRX) disclosures and growth. The firm finds the slides "interesting," and says Allergan management last week noted that its current business "has never been stronger." BMO thinks investors should own Allergan, and sees the upcoming Q2 results as a potential catalyst. The firm has an Outperform rating on the name with a $202 price target.
News For AGN;VRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 26, 2015
17:34 EDTAGNActavis registration statement for Allergan acquisition declared effective
Subscribe for More Information
January 22, 2015
05:57 EDTVRXActavis, Valeant raise prospects of more healthcare deals, Financial Times says
Subscribe for More Information
January 21, 2015
12:30 EDTAGN, VRXGlaxoSmithKline 'admired' by Pfizer CEO, FT reports
Subscribe for More Information
07:22 EDTAGNActavis price target raised to $330 from $280 at Deutsche Bank
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use